Loading
Latest filing published 08 Jan 2025 for Entero Therapeutics, Inc., €451.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Sarah Romano (finance chief) discloses dealings in 2 companies, chiefly Kiora Pharmaceuticals Inc and GridAI Technologies Corp. The record holds 52 filings, for trades running from 6 February 2017 to 6 January 2025.
Market trades split into 3 purchases (€8,517) and 12 sales (€19k). The totals do not cover 2 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 36 share grants. Since January 2025: no purchases and 1 sale on the market.
On 8 January 2025 came the latest disclosure, an open-market sale for €451 in GridAI Technologies Corp. The latest purchase dates back some time: it was published 3,110 days ago, on 18 April 2018. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations